John Higgins Sells 20,000 Shares of OmniAb, Inc.

On June 17, 2026, John Higgins, an insider at OmniAb, Inc. (NasdaqGM: OABI), sold 20,000 shares of the company. The transaction did not involve a pre-planned trading program. At the time, OmniAb shares were trading at $2.34.

Other Institutional Activity in OmniAb

Several institutional investors have adjusted their positions in OmniAb. BlackRock, Inc. increased its stake by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.7 million. Meanwhile, Cadian Capital Management reduced its holdings by 277,825 shares, now holding 4,157,129 shares worth about $6.5 million. Geode Capital Management also boosted its position by 202,887 shares, totaling 2,925,579 shares valued at roughly $4.6 million.

OmniAb, Inc. Stock Snapshot

Shares of OmniAb, Inc. (NasdaqGM: OABI) were recently trading around $2.34. The company has a market capitalization of approximately $339.2 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock has seen a 52-week low of $1.3 and a high of $2.79. OmniAb's 50-day moving average is $1.97, and the 200-day moving average is $1.80. The company has a current ratio of 4.80 and a quick ratio of 4.55, indicating strong liquidity, with a debt-to-equity ratio of 7.49.

Recent Earnings

OmniAb, Inc. reported revenue of $28.9 million, with a modest growth rate of 2.47%. However, the company posted a net margin of -187.59% and a return on equity of -20.25%, reflecting ongoing challenges in profitability. Its next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for OmniAb. On August 7, 2025, RBC Capital maintained a "buy" rating with a target price of $3. Benchmark reiterated its "buy" rating with a $6 target on May 12, 2025. HC Wainwright & Co. also reiterated a "buy" rating with an $11 target on March 19, 2025. The consensus among analysts is a "buy," with a mean target price of $7.33 based on six opinions.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It provides discovery research technology to pharmaceutical and biotech firms worldwide, aiding in the discovery of therapeutic antibodies. The company's OmniAb platform uses biological intelligence to create optimized antibody candidates. It employs various transgenic animals for antibody generation, including OmniRat, OmniChicken, and OmniMouse, and offers AI tools for therapeutic discovery. The company was founded in 2012 and is led by CEO Matthew W. Foehr.

Bottom Line

John Higgins' sale of OmniAb shares is part of routine insider activity. Investors often watch these trades for potential insights, but they don't necessarily indicate a negative outlook. OmniAb continues to hold interest from institutional investors like BlackRock and analysts maintaining positive ratings. As always, remember that 13F filings and insider transactions are backward-looking and may not reflect the current market position.